Janson B, Prasomthong J, Malakul W, Boonsong T, Tunsophon S Hibiscus sabdariffa L. calyx extract prevents the adipogenesis of 3T3-L1 adipocytes, and obesity-related insulin resistance in high-fat diet-induced obese rats. Biomed Pharmacother. 2021 Jun;138:111438. doi: 10.1016/j.biopha.2021.111438. Epub 2021 Mar 13.
Li S, Wu B, Fu W, Reddivari L The Anti-inflammatory Effects of Dietary Anthocyanins against Ulcerative Colitis. Int J Mol Sci. 2019 May 27;20(10):2588. doi: 10.3390/ijms20102588.
Marhuenda J, Perez S, Victoria-Montesinos D, Abellan MS, Caturla N, Jones J, Lopez-Roman J A Randomized, Double-Blind, Placebo Controlled Trial to Determine the Effectiveness a Polyphenolic Extract (Hibiscus sabdariffa and Lippia citriodora) in the Reduction of Body Fat Mass in Healthy Subjects. Foods. 2020 Jan 6;9(1):55. doi: 10.3390/foods9010055. Erratum In: Foods. 2020 Mar 03;9(3):
Sayago-Ayerdi SG, Goni I [Hibiscus sabdariffa L: source of antioxidant dietary fiber]. Arch Latinoam Nutr. 2010 Mar;60(1):79-84. Spanish.
Sayago-Ayerdi SG, Venema K, Tabernero M, Sarria B, Bravo L, Mateos R Bioconversion of polyphenols and organic acids by gut microbiota of predigested Hibiscus sabdariffa L. calyces and Agave (A. tequilana Weber) fructans assessed in a dynamic in vitro model (TIM-2) of the human colon. Food Res Int. 2021 May;143:110301. doi: 10.1016/j.foodres.2021.110301. Epub 2021 Mar 10.
Wolever TM, Jenkins DJ The use of the glycemic index in predicting the blood glucose response to mixed meals. Am J Clin Nutr. 1986 Jan;43(1):167-72. doi: 10.1093/ajcn/43.1.167.
Bioavailability of Antioxidant Compounds and Effect on Markers of Inflammation by Ingestion of a Hibiscus Sabdariffa Beverage With Glicemic and Insulinemic Response
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.